To test the above hypothesis that, like mutant p53, RUNX2 could contribute to SAHA resistance of p53-mutated pancreatic cancer cells, we sought to assess the possible impact of RUNX2 knockdown on SAHA-mediated cell death and mutant p53 expression in MiaPaCa-2 cells. Here, TP53 is linked to pancreatic neoplasm.